Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Solution Vehicle Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02688556
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine, vehicle of OTX-101
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Rancho Cordova, California • Edgewood, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

NCT01023841
View directory record Official record
Conditions
Eyelash Hypotrichosis, Alopecia Areata
Interventions
bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169
View directory record Official record
Conditions
Atopic Disease (Including Allergic Conjunctivitis)
Interventions
Drug: AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 23, 2026, 8:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

NCT05992922
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
IC265 Ophthalmic Solution 1%, Placebo Ophthalmic Solution (Vehicle)
Drug
Lead sponsor
Iacta Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT05896670
View directory record Official record
Conditions
Dry Eye Disease
Interventions
licaminlimab, vehicle of OCS-02, Artificial tears
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Newport Beach, California • Colorado Springs, Colorado • Shelby, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Study of SOR007 Ointment for Actinic Keratosis

NCT03083470
View directory record Official record
Conditions
Actinic Keratosis
Interventions
SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
Drug · Other
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
45 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 23, 2026, 8:32 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Early Phase 1 Interventional

Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)

NCT02710162
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Micro Mouth Pressure Meter, Iowa Oral Performance Instrument, Electrical Impedance Myography, Capsaicin, Videofluoroscopic Swallowing Study, Pulmonary Function Testing, Swallowing Related Quality of Life Questionnaire, Functional Oral Intake Scale, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Eating Assessment Tool-10, Communicative Effectiveness Survey, The Center for Neurologic Studies Bulbar Function Scale
Device · Drug · Procedure + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

NCT03598699
View directory record Official record
Conditions
Dry Eye
Interventions
AXR-159, Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

NCT03229759
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
Octenidine Dihydrocloride in aqueous solution, Vehicle Control, Saline Control
Drug · Other
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

NCT00364091
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 0.025% ophthalmic solution
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Louisville, Kentucky • North Andover, Massachusetts • Creve Coeur, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

NCT00423007
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

NCT01933464
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Cromolyn Sodium, Normal Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

NCT03565887
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
36
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 23, 2026, 8:32 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529
View directory record Official record
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Early Phase 1 Interventional

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

NCT06273852
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0405
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 8:32 AM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT01687426
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 23, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

NCT02974907
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 8:32 AM EDT